| Cardiac Fibrosis and Remodeling | Lifetime | 9 | DE 1 | 99.69 |
| Cardiac Structural Anomalies and Repair | Lifetime | 32 | DE 3 | 99.82 |
| Cardiovascular Issues in Pregnancy | Lifetime | 21 | DE 3 | 99.63 |
| Nitric Oxide and Endothelin Effects | Lifetime | 60 | DE 8 | 99.67 |
| Heart Failure Treatment and Management | Lifetime | 95 | DE 5 | 99.62 |
| Apelin-related biomedical research | Lifetime | 22 | DE 6 | 98.53 |
| Hormonal Regulation and Hypertension | Lifetime | 139 | DE 21 | 99.20 |
| Takotsubo Cardiomyopathy and Associated Phenomena | Lifetime | 16 | DE 4 | 98.51 |
| Signaling Pathways in Disease | Lifetime | 85 | DE 3 | 98.78 |
| MicroRNA in disease regulation | Lifetime | 402 | DE 26 | 98.61 |
| Mechanical Circulatory Support Devices | Lifetime | 213 | DE 18 | 98.93 |
| Cardiovascular Function and Risk Factors | Lifetime | 430 | DE 20 | 99.21 |
| Cardiovascular, Neuropeptides, and Oxidative Stress Research | Lifetime | 44 | DE 2 | 98.36 |
| Cardiac pacing and defibrillation studies | Lifetime | 387 | DE 19 | 98.83 |
| Diabetes Treatment and Management | Lifetime | 565 | DE 34 | 98.00 |
| Angiogenesis and VEGF in Cancer | Lifetime | 526 | DE 42 | 96.88 |
| Antiplatelet Therapy and Cardiovascular Diseases | Lifetime | 529 | DE 32 | 97.64 |
| Circular RNAs in diseases | Lifetime | 602 | DE 22 | 96.62 |
| Eicosanoids and Hypertension Pharmacology | Lifetime | 476 | DE 37 | 97.16 |
| Neutrophil, Myeloperoxidase and Oxidative Mechanisms | Lifetime | 405 | DE 40 | 96.55 |
| Potassium and Related Disorders | Lifetime | 161 | DE 5 | 96.83 |
| Renin-Angiotensin System Studies | Lifetime | 433 | DE 40 | 96.17 |
| Cardiac Structural Anomalies and Repair | 2021-2025 | 6 | DE 3 | 99.85 |
| Cardiac Fibrosis and Remodeling | 2021-2025 | 2 | DE 1 | 98.54 |
| Cardiovascular Issues in Pregnancy | 2021-2025 | 7 | DE 1 | 99.11 |
| Cardiac pacing and defibrillation studies | 2021-2025 | 26 | DE 1 | 99.57 |
| Heart Failure Treatment and Management | 2021-2025 | 37 | DE 2 | 99.65 |
| Cardiovascular Function and Risk Factors | 2021-2025 | 142 | DE 10 | 98.99 |
| Diabetes Treatment and Management | 2021-2025 | 95 | DE 7 | 98.84 |
| Mechanical Circulatory Support Devices | 2021-2025 | 86 | DE 8 | 98.38 |
| Hormonal Regulation and Hypertension | 2021-2025 | 80 | DE 13 | 96.38 |
| Potassium and Related Disorders | 2021-2025 | 24 | DE 2 | 97.78 |
| Cardiac Arrhythmias and Treatments | 2021-2025 | 404 | DE 41 | 96.77 |
| Peptidase Inhibition and Analysis | 2021-2025 | 302 | DE 40 | 93.84 |
| Atrial Fibrillation Management and Outcomes | 2021-2025 | 612 | DE 56 | 95.83 |
| Signaling Pathways in Disease | 2021-2025 | 45 | DE 5 | 88.77 |
| Cardiac electrophysiology and arrhythmias | 2021-2025 | 712 | DE 54 | 91.65 |
| Takotsubo Cardiomyopathy and Associated Phenomena | 2021-2025 | 55 | DE 8 | 88.78 |
| Cardiovascular Effects of Exercise | 2021-2025 | 508 | DE 19 | 88.45 |
| Electrolyte and hormonal disorders | 2021-2025 | 733 | DE 40 | 64.57 |
| GDF15 and Related Biomarkers | 2021-2025 | 538 | DE 35 | 56.56 |
